June 10, 2020 -- Panacea Biotec and Refana are partnering on an inactivated virus-based vaccine for COVID-19 through a joint venture company that will be based in Ireland.
Panacea will handle product development and commercial manufacturing, and the venture company will be responsible for clinical development and regulatory submissions worldwide. Panacea and Refana will handle sales and distribution of the vaccine in their respective territories.
Refana aims to manufacture over 500 million doses of the COVID-19 vaccine candidate, with over 40 million doses expected to be available for delivery in early 2021.